Tempest Therapeutics Inc Stock Price, News & Analysis

Tempest Therapeutics (TPST) announced the start of a Phase 1b/2 clinical trial for its TPST-1120 therapy in collaboration with Roche, aimed at treating hepatocellular carcinoma (HCC). The company reported a cash position of $59.8 million as of September 30, 2021, up from $18.8 million in December 2020, primarily due to a merger. However, net losses were $8.1 million for Q3 2021, increasing from $5.4 million in Q3 2020. Research and development expenses rose to $4.6 million, reflecting increased operational costs. Tempest anticipates sufficient resources to continue operations into Q2 2023.

Tempest Therapeutics (Nasdaq: TPST) announced participation in two investor conferences this November. The company will present at the Jefferies London Healthcare Conference on November 18, 2021, with an on-demand presentation available at 8:00 a.m. GMT. Additionally, they will engage in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, available at 10:00 a.m. ET. Tempest is focused on developing innovative oncology therapeutics, including TPST-1495 and TPST-1120, which are currently in Phase 1 studies.

Tempest Therapeutics (Nasdaq: TPST) announced that the U.S. Patent Office has issued multiple patents for its therapeutic candidate TPST-1495, an orally available small molecule targeting EP2 and EP4 receptors in the PGE2 pathway. This dual antagonist shows enhanced potency in pre-clinical studies compared to single EP4 inhibitors and could address tumor progression and immune suppression linked to PGE2 signaling. The patent portfolio, now including U.S. Patent Numbers 10,968,201 and 11,066,405, strengthens Tempest's IP for TPST-1495's use, which is currently in Phase 1 clinical trials for advanced solid tumors.

Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of a presentation for TPST-1495 at the Society for Immunotherapy of Cancer’s 36th Annual Meeting scheduled for November 10-14, 2021. The presentation, titled "Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway", will highlight preclinical studies showing TPST-1495's enhanced efficacy over single antagonists against tumor progression and immune suppression. Tempest is currently advancing TPST-1495 in a Phase 1a/1b clinical trial targeting advanced solid tumors.

Tempest Therapeutics (TPST) has announced the start of a Phase 1b/2 clinical study for TPST-1120, a PPAR⍺ antagonist, in combination with atezolizumab and bevacizumab for advanced hepatocellular carcinoma (HCC). The trial, conducted in partnership with Roche, will assess the safety and anti-tumor activity of this combination in up to 60 patients across multiple sites. HCC presents significant treatment challenges, highlighting the need for new therapy options. Tempest retains global rights to TPST-1120, which has shown promise in preclinical studies.

Tempest Therapeutics (Nasdaq: TPST) announced on September 13, 2021, the appointment of Russell Vance, PhD, to its advisory board and an exclusive licensing agreement with the University of California at Berkeley. This license covers a new drug target identified in Dr. Vance's lab, which has potential implications for cancer treatment. Dr. Vance's research focuses on a pathway involved in immune response and tumor metastasis. The company continues to advance its clinical programs, including TPST-1495 and TPST-1120, both currently in Phase 1 studies.

Tempest Therapeutics, Inc. (Nasdaq: TPST) has announced its participation in two upcoming investor conferences in September 2021. The company will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. ET and at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 9:55 a.m. ET. Tempest is progressing its clinical-stage oncology programs, including TPST-1495 and TPST-1120, which target cancer treatment through innovative mechanisms. For more details, visit the Tempest investor website.

Science 37 has appointed Christine Pellizzari as the new Chief Legal Officer, bringing nearly 30 years of legal experience to enhance the company's mission of accelerating clinical trials. Previously serving at Insmed, Pellizzari's expertise will support Science 37's global expansion and improve access to clinical research for patients and providers. CEO David Coman emphasized her qualifications as instrumental in navigating the evolving decentralized clinical trial landscape.

Tempest Therapeutics (TPST) successfully completed a merger, raising $30M through a PIPE, boosting its cash reserves to $68.5M. The company advanced its clinical programs, including TPST-1495 and TPST-1120, showing promising results in patient trials. The net loss for Q2 2021 was $7.1M, higher than the previous year's $5.2M, mainly due to merger-related expenses. R&D expenses increased slightly to $4.2M. Looking forward, significant milestones are expected in 2022, including new studies for TPST-1495 and TPST-1120.